Intervacc AB (publ) (STO: IVACC)

Market Cap	290.83M
Revenue (ttm)	10.26M
Net Income (ttm)	-102.66M
Shares Out	75.74M
EPS (ttm)	-1.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	68,508
Open	3.780
Previous Close	3.780
Day's Range	3.740 - 4.000
52-Week Range	2.900 - 10.460
Beta	0.68
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Intervacc AB

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against Strep. suis for the treatment of piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep. The co...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1983
• Employees: 15
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IVACC

Financial Performance

In 2023, ERMA's revenue was 1.36 million, a decrease of -80.17% compared to the previous year's 6.85 million. Losses were -44.61 million, 6.15% more than in 2022.